These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16869810)
1. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Oton E; Barcena R; Moreno-Planas JM; Cuervas-Mons V; Moreno-Zamora A; Barrios C; Garcia-Garzon S; Moreno A; Boullosa-Graña E; Rubio-Gonzalez EE; Garcia-Gonzalez M; Blesa C; Mateos ML Am J Transplant; 2006 Oct; 6(10):2348-55. PubMed ID: 16869810 [TBL] [Abstract][Full Text] [Related]
2. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356 [TBL] [Abstract][Full Text] [Related]
3. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Al-Hamoudi W; Mohamed H; Abaalkhail F; Kamel Y; Al-Masri N; Allam N; Alqahtani S; Al-Sofayan M; Khalaf H; Al-Sebayel M; Al-Jedai A; Abdo A Dig Dis Sci; 2011 Jun; 56(6):1848-52. PubMed ID: 21221800 [TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases. Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137 [TBL] [Abstract][Full Text] [Related]
5. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839 [TBL] [Abstract][Full Text] [Related]
6. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585 [TBL] [Abstract][Full Text] [Related]
7. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Babatin M; Schindel L; Burak KW Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090 [TBL] [Abstract][Full Text] [Related]
9. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Lodato F; Berardi S; Gramenzi A; Mazzella G; Lenzi M; Morelli MC; Tame MR; Piscaglia F; Andreone P; ; Ballardini G; Bernardi M; Bianchi FB; Biselli M; Bolondi L; Cescon M; Colecchia A; D'Errico A; Del Gaudio M; Ercolani G; Grazi GL; Grigioni W; Lorenzini S; Pinna AD; Ravaioli M; Roda E; Sama C; Vivarelli M Aliment Pharmacol Ther; 2008 Aug; 28(4):450-7. PubMed ID: 18549463 [TBL] [Abstract][Full Text] [Related]
10. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712 [TBL] [Abstract][Full Text] [Related]
11. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Fontana RJ; Hughes EA; Appelman H; Hindes R; Dimitrova D; Bifano M Liver Transpl; 2012 Sep; 18(9):1053-9. PubMed ID: 22706796 [TBL] [Abstract][Full Text] [Related]
12. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382 [TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434 [TBL] [Abstract][Full Text] [Related]
14. Sustained virological response: a milestone in the treatment of chronic hepatitis C. Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416 [TBL] [Abstract][Full Text] [Related]
15. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854 [TBL] [Abstract][Full Text] [Related]
16. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin. Dogan UB; Akin MS; Yalaki S Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912 [TBL] [Abstract][Full Text] [Related]
17. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F; Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096 [TBL] [Abstract][Full Text] [Related]
19. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988 [TBL] [Abstract][Full Text] [Related]
20. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]